Citation:Sharif W,Sharif Z.Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders.Int J Ophthalmol 2017;10(3):480-484,doi:10.18240/ijo.2017.03.24
Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders
Received:April 25, 2016  Revised:August 19, 2016
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2017.03.24
Key Words:retina; Leber’s congenital amaurosis; Leber’s congenital amaurosis type 2; choroideremia; achromatopsia; cyclic nucleotide gated channel alpha 3; retinoid isomerohydrolase; gene therapy
Fund Project:
     
AuthorInstitution
Walid Sharif Department of Ophthalmology Birmingham & Midland Eye Centre, City Hospital NHS Trust, Birmingham B18 7QH, UK
Zuhair Sharif Institute of Ophthalmology, University College London 11-43 Bath St, London EC1V 9EL, UK
Hits: 618
Download times: 228
Abstract:
      Leber’s congenital amaurosis (LCA) and recent gene therapy advancement for treating inherited retinopathies were extensive literature reviewed using MEDLINE, PubMed and EMBASE. Adeno-associated viral vectors were the most utilised vectors for ocular gene therapy. Cone photoreceptor cells might use an alternate pathway which was not reliant of the retinal pigment epithelium (RPE) derived retinoid isomerohydrolase (RPE65) to access the 11-cis retinal dehydechromophore. Research efforts dedicated on the progression of a gene-based therapy for the treatment of LCA2. Such gene therapy approaches were extremely successful in canine, porcine and rodent LCA2 models. The recombinant AAV2.hRPE65v2 adeno-associated vector contained the RPE65 cDNA and was replication deficient. Its in vitro injection in target cells induced RPE65 protein production. The gene therapy trials that were so far conducted for inherited retinopathies have generated promising results. Phase I clinical trials to cure LCA and choroideremia demonstrated that adeno-associated viral vectors containing RPE genes and photoreceptors respectively, could be successfully administered to inherited retinopathy patients. A phase III trial is presently ongoing and if successful, it will lead the way to additional gene therapy attempts to cure monogenic, inherited retinopathies.
PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360787/
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment